Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel

被引：107

作者：

McConathy, Walter J. ^{[2
]}

Nair, Maya P. ^{[1
]}

Paranjape, Sulabha ^{[2
]}

Mooberry, Linda ^{[1
]}

Lacko, Andras G. ^{[1
]}

机构：

[1] Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA

[2] Univ N Texas, Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX 76107 USA

来源：

ANTI-CANCER DRUGS | 2008年 / 19卷 / 02期

关键词：

chemotherapy; drug delivery; nanoparticles; reconstituted (synthetic) high-density lipoprotein;

D O I：

10.1097/CAD.0b013e3282f1da86

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Reconstituted (synthetic) high-density lipoprotein particles carrying paclitaxel (rHDL/PTX) were prepared with substantially higher PTX content than reported earlier. The rHDL/PTX complexes seemed to be primarily spherical nanoparticles when examined via electron microscopy, with a constant composition, molecular weight and exceptional stability even after ultracentrifugation and storage for up to 6 months. The rHDL/PTX nanoparticles; had superior cytotoxicity against several cancer cell lines (MCF7, DU145, OV1063 and OVCAR-3), the half maximal inhibitory concentration (IC50) having been found to be 5-20 times lower than that of the free drug. Studies with mice showed that the rHDL/PTX nanoparticles were substantially better tolerated than the corresponding dosages of either Taxol or Abraxane.

引用

页码：183 / 188

页数：6

共 30 条

[21]

MARKEL A, 2004, ISRAEL J MED SCI, V30, P787

[22]

MATZ CE, 1982, J BIOL CHEM, V257, P4535

[23] Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme [J].

Nikanjam, Mina ;

Blakely, Eleanor A. ;

Bjornstad, Kathleen A. ;

Shu, Xiao ;

Budinger, Thomas F. ;

Forte, Trudy M. .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 328 (01) :86-94

[24] Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences [J].

Owens, MD ;

Baillie, G ;

Halbert, GW .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 228 (1-2) :109-117

[25]

Peterson C, 1991, Targeted Diagn Ther, V5, P175

[26] Optimized bacterial expression of human apolipoprotein A-I [J].

Ryan, RO ;

Forte, TM ;

Oda, MN .

PROTEIN EXPRESSION AND PURIFICATION, 2003, 27 (01) :98-103

[27]

TERPSTRA AH, 1981, ANAL BIOCHEM, V111, P49

[28] Cardiovascular risk factors in Mexican-American children at risk for type 2 diabetes mellitus (T2DM) [J].

Urrutia-Rojas, X ;

Menchaca, J ;

Wadley, W ;

Ahmad, N ;

Lacko, A ;

Bae, S ;

Spellman, C ;

Kudchodkar, B ;

Kudolo, G ;

McConathy, W .

JOURNAL OF ADOLESCENT HEALTH, 2004, 34 (04) :290-299

[29] UPTAKE OF LOW-DENSITY LIPOPROTEINS BY HUMAN LEUKEMIC-CELLS INVIVO - RELATION TO PLASMA-LIPOPROTEIN LEVELS AND POSSIBLE RELEVANCE FOR SELECTIVE CHEMOTHERAPY [J].

VITOLS, S ;

ANGELIN, B ;

ERICSSON, S ;

GAHRTON, G ;

JULIUSSON, G ;

MASQUELIER, M ;

PAUL, C ;

PETERSON, C ;

RUDLING, M ;

SODERBERGREID, K ;

TIDEFELT, U .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) :2598-2602

[30] Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents [J].

Zheng, G ;

Chen, J ;

Li, H ;

Glickson, JD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (49) :17757-17762

← 1 2 3 →